Dr Reddy's Laboratories stock gains as Q1 profit falls

Published on 09/23/2026 at 15:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dr Reddy's Laboratories stock traded at INR 1,213 on September 23, 2026, while Q1 FY27 revenue fell 5.6 percent. Net profit dropped 68.7 percent year over year.

RDY, US2565981035, Illustration mit AI erstellt.

Dr Reddy's Laboratories Ltd. (US2565981035) traded at INR 1,213 on the NSE at 12:44 p.m. IST on September 23, 2026, up 0.17 percent on the session. The move came as the latest reported quarter showed weaker revenue and profit, keeping operating margins at the center of the stock story.

Q1 revenue falls 5.6 percent

In Q1 FY27, revenue from operations fell 5.55 percent year over year to INR 8,070.5 crore, according to Tickertape on September 23, 2026. Profit before tax declined 70.98 percent year over year to INR 552.6 crore in the quarter ended June 30, 2026.

The earnings decline was sharper than the top-line contraction. Consolidated net profit fell 68.67 percent year over year to INR 444.30 crore in Q1 FY27, compared with INR 1,418.10 crore in Q1 FY26, according to Tickertape on September 23, 2026. That comparison makes profitability the more important variable than revenue alone.

Margin pressure remains visible

Q1 FY27 adjusted EBITDA margin stood at 15.4 percent, while the reported EBITDA margin was 12.5 percent, according to Scanx on September 23, 2026. The same report placed diluted EPS at INR 5.32 for the quarter, down from INR 17.00 in the year-earlier period.

The reported gross margin fell 1,039 basis points year over year to 46.5 percent in Q1 FY27. The pressure was linked to lower lenalidomide sales, a semaglutide API provision and higher solvent costs, while the gross margin excluding the provision was 49.4 percent, according to Scanx on September 23, 2026.

Stock remains below yearly high

The September 23 NSE quote of INR 1,213 stood below the 52-week high of INR 1,415 and above the 52-week low of INR 1,101, based on the September 22 market range reported by 5paisa on September 22, 2026. The September 22 close was INR 1,211, up 1.06 percent from INR 1,198, with volume of 3,502,652 shares and market capitalization near INR 101,079 crore.

For the next earnings checkpoint, the board is scheduled to consider results for the quarter ending September 30, 2026, on October 23, 2026, according to Tickertape on September 23, 2026. The date gives the market a defined point for reassessing whether margins recover from the Q1 FY27 level.

INR 1,213 marks current level

Dr Reddy's Laboratories stock traded at INR 1,213 on the NSE as of 12:44 p.m. IST on September 23, 2026, up 0.17 percent. The quote sits INR 202 below the reported 52-week high of INR 1,415.